Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa
- First Online:
- 323 Downloads
We present our experience with five cases of pandrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia (VAP) and analysis of risk factors.
Design and setting
Case-control study in a 15-bed intensive care unit (ICU).
Patients and participants
The study included 5 cases and 20 controls. Each case patient was matched to four contemporary controls according to gender, prior hospital admissions, hospitalization duration, ICU admission cause, Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Function Assessment (SOFA) scores on ICU admission, and length of ICU stay, and mechanical ventilation duration until first VAP episode by a multidrug-resistant bacterium.
Measurements and results
Recorded variables included age, gender, daily APACHE II and SOFA scores, patient medication, treatment interventions, positive cultures and corresponding antibiograms, occurrence of infection, sepsis, and septic shock, other ICU-associated morbidity, length of ICU stay and mechanical ventilation, and patient outcome. Healthcare worker and environmental cultures, and a hand-disinfection survey were performed. Pandrug-resistant P. aeruginosa isolates belonged to the same genotype and were blaVIM–1-like gene positive. The outbreak resolved following reinforcement of infection-control measures (September 27). The sole independent predictor for pandrug-resistant P. aeruginosa VAP was combined use of carbapenem for more than 20 days and colistin use for and more than 13 days (odds ratio 76.0; 95% confidence interval 3.7–1487.6). An additional risk factor was more than 78 open suctioning procedures during 6–26 September (odds ratio 16.0; 95% confidence interval 1.4–185.4).
Prolonged carbapenem-colistin use predisposes to VAP by pandrug-resistant P. aeruginosa. Cross-transmission may be facilitated by open suctioning.
KeywordsDisease outbreaks Pseudomonas aeruginosa Carbapenems β-Lactamases Colistin
- 5.Routsi C, Platsouka E, Willems RJL, Bonten MJ, Paniara O, Saroglou G, Roussos C (2003) Detection of enterococcal surface protein gene (esp) and amplified length polymorphism typing of glycopeptide-resistant Enterococcus faecium during its emergence in a greek intensive care unit. J Clin Microbiol 41:5472–5746CrossRefGoogle Scholar
- 6.Giacometti A, Cirioni O, Del Prete MS, Barchesi F, Fortuna M, Drenaggi D, Scalise G (2000) In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. Antimicrob Agents Chemother 44:1716–1719PubMedCrossRefGoogle Scholar
- 7.Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME (2005) Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 49:3136–3146PubMedCrossRefGoogle Scholar
- 9.American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644–1655Google Scholar
- 10.Clinical Laboratory Standards Institute (2006) Performance standards for antimicrobial susceptibility testing; sixteenth Informational Supplement M100-S16Google Scholar
- 15.Laupland K, Perkins MD, Church DL, Gregson DB, Louie TJ, Conly JM, Elsayed S, Pitout JD (2005) Population-based epidemiological study of infections caused by carbapenem-resistant pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-b-lactamase (MBL)-producing strains. J Infect Dis 192:1606–1612PubMedCrossRefGoogle Scholar
- 16.Katz MH (1999) Introduction. In: Katz MH (ed). Multivariable analysis, 1st edn. Cambridge University Press, New York, pp 1–16Google Scholar